Premium
A tyrosinase peptide presented by HLA‐B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes
Author(s) -
Morel Sandra,
Ooms Annie,
Van Pel Aline,
Wölfel Thomas,
Brichard Vincent G.,
Van der Bruggen Pierre,
Van den Eynde Benoît J.,
Degiovanni Gérard
Publication year - 1999
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19991210)83:6<755::aid-ijc10>3.0.co;2-s
Subject(s) - ctl* , cytotoxic t cell , human leukocyte antigen , tyrosinase , melanoma , peptide , immunotherapy , immunology , antigen , biology , in vitro , immune system , cancer research , biochemistry , enzyme
We previously described different cytotoxic T lymphocyte (CTL) clones isolated from the blood lymphocytes of a melanoma patient after in vitro stimulation with autologous tumor cells. These CTL clones recognized at least 2 distinct antigens on the melanoma cells. Here, we show that one of them consists of a peptide derived from tyrosinase and presented by HLA‐B35. The peptide is 9 amino acids long and has the sequence LPSSADVEF. It can be presented by the 2 major B35 allelic subtypes, B*3501 and B*3503. As HLA‐B35 is one of the most frequent HLA‐B specificities, being present in about 20% of Caucasian individuals, it may be a useful target for peptide‐based immunotherapy of melanoma. Int. J. Cancer 83:755–759, 1999. © 1999 Wiley‐Liss, Inc.